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Implementation of pharmacogenomics (PGx) in clinical care can lead to improved drug efficacy and reduced
adverse drug reactions. However, there has been a lag in adoption of PGx tests in clinical practice. This is due in
part to a paucity of rigorous systems for translating published clinical and scientific data into standardized
diagnostic tests with clear therapeutic recommendations. Here we describe the Pharmacogenomics Appraisal,
Evidence Scoring and Interpretation System (PhAESIS), developed as part of the Coriell Personalized Medicine
Collaborative research study, and its application to seven commonly prescribed drugs.Background
It has long been recognized that there is significant vari-
ability in drug response with respect to efficacy, optimal
dose, and adverse drug reactions (ADRs). Pharmacogen-
omics (PGx), the study of the genes and genetic poly-
morphisms that influence variability in drug response,
has the potential to both personalize and optimize drug
therapy. Because of this potential for improvement in ef-
ficacy and for reduction in ADRs and their associated
morbidity, mortality, and cost, there is increasing inter-
est in integrating PGx into routine clinical care [1-9].
However, despite the many examples of causative links
between genetic variations and substantial inter-
individual differences in drug effects, and the fact that as
many as 10% of labels for drugs approved by the Food
and Drug Administration (FDA) contain PGx informa-
tion [10], the development of validated diagnostic tests
and the uptake of the PGx information by clinicians has
been slow. The future success of PGx integration in
personalized medicine will depend on a number of key
factors, including 1) well-designed diagnostic tools that
accurately identify all patients of different ancestral
backgrounds who can benefit from the targeted* Correspondence: ngharani@coriell.org
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reproduction in any medium, provided the ortherapies [10]; 2) a robust infrastructure for linking gen-
etic test results (ideally available pre-emptively) and
therapeutic recommendations to the drug-prescribing
decision makers, for example, through the electronic
medical record (EMR); and 3) an expansion of genomics
and pharmacogenomics education programs for healthcare
professionals so that they are sufficiently well-informed to
use the information to manage their patients’ care.
Both the need for accurate standardized diagnostic
tools and a robust infrastructure for linking genetics and
therapeutic recommendations require a rigorous system
for translating the published clinical and scientific data
into clear drug-specific interpretations. Such a system
should identify the genetic components that have
sufficient data to support clinical or diagnostic utility,
present evidence-based interpretations of genetic re-
sults in the context of particular drugs, provide clear
recommendations for the application of specific re-
sults, and highlight areas with gaps in knowledge that
need further investigation. The outcome of such a crit-
ical appraisal should guide further studies aimed both
at addressing the specific gaps in knowledge about a
gene’s effects on a specific drug (termed a ‘drug-gene
pair’) and at validating further the predictive bio-
markers, thus allowing therapeutics and diagnostics
developers and regulators to make meaningful risk-
benefit assessments that will pave the way to clinicall Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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multifaceted approach that includes routine integra-
tion of PGx in the design and outcomes analysis of
clinical drug trials; retrospective studies that link pa-
tient health outcomes with medical/medication histor-
ies, gleaned through self-reported or EMR data [12,13];
and prospective, population-based, comparative effect-
iveness research [14,15].
The Coriell Personalized Medicine Collaborative
(CPMC) has developed a systematic process for the
critical appraisal, evidence scoring, and interpretation
of PGx data (the Pharmacogenomics Appraisal, Evi-
dence Scoring and Interpretation System; PhAESIS) to
evaluate and address some of the current obstacles to
PGx implementation highlighted above. This process
was created in support of the ongoing CPMC study, an
institutional review board-approved prospective obser-
vational study designed to evaluate the utility of per-
sonalized genomic information in health management.
An overview of the CPMC project [16] and the CPMC
approach to genetic risk estimation for health condi-
tions [17] has been described elsewhere. Briefly, study
participants with consent provide saliva samples for
genotyping. Then, using a secure web-based interface,
the CPMC provides participants with educational ma-
terial, collects self-reported participant data (such as
medical history, medication use, family history, life-
style factors, and optional follow-up outcome surveys),
and reports personalized results for potentially action-
able health conditions and genetic results related to
medication response. Genetic and self-reported data
are used to conduct both replication and discovery
genetic analyses, and to evaluate participant use of the
results over time. The CPMC utilizes two independent
Advisory Groups: the Pharmacogenomics Advisory Group
(PAG), which provides guidance on PGx risk reporting,
and the Informed Cohort Oversight Board (ICOB), which
provides guidance on reporting to study participants of
their risk for common complex diseases.
In order to comprehend the current validity and util-
ity of published PGx data, to effectively interpret this
information, and to return a clinically meaningful PGx
risk report for the study participants, CPMC scientists
identified the need to develop a systematic process
for critically evaluating and translating published
drug-specific PGx data for risk reporting. The method de-
veloped is drug-centric, utilizes a multi-tier evidence-
based scoring procedure to define key genetic variants
influencing variation in drug response, highlights gaps
in knowledge, involves guidance by an external advis-
ory committee, and presents drug–response interpre-
tations for use in clinical reporting of genetic results.
Here, we describe the CPMC PhAESIS system, de-
signed to guide the development of the CPMC drugPGx risk reports, and its application to individual
drug-gene pairs.
Methods
The CPMC PhAESIS process broadly comprises six
steps as described below (summarized in Figure 1). Cu-
rated data from steps 2 to 6 are prepared as PhAESIS
summary documents for review by the CPMC Pharma-
cogenomics Advisory Group (PAG). If approved by the
PAG, drug-specific risk reports are then developed and
released to study participants.
Candidate drug selection
Candidate drugs for PGx reporting are identified and
prioritized for the CPMC study based on a number of
criteria: 1) inclusion in the FDA label (Table of Pharma-
cogenomic Biomarkers in Drug Labels) [18]; 2) descrip-
tion in scientific or clinical publications or in relevant
PGx databases, such as the Pharmacogenomics Knowl-
edgebase (PharmGKB) [19] and the Cytochrome P450
Drug Interaction Table at Indiana University School of
Medicine [20]; 3) clinical significance (effect and sever-
ity) of altered drug response (for example, a genetic re-
sult associated with a life-threatening ADR or presence
of a relevant ‘black box’ warning on the FDA drug label);
4) potential actionability, as defined by the ability to alter
prescribing practice (dosing or alternate therapy) or clin-
ical management such as more frequent monitoring, to
potentially mitigate risk of ADRs or to maximize drug
efficacy; 5) national drug usage statistics [21,22]; and 6)
CPMC cohort drug usage data (see Additional file 1:
Table S1 for web-based PGx resources used for drug se-
lection). Each of these parameters can be assessed and
used to prioritize selection of a candidate drug or class
of drugs for CPMC PhAESIS evaluation.
Identification of key PGx gene(s) and drug-specific key
genetic variants
Once a drug is selected for evaluation, the FDA drug
label, the peer-reviewed scientific and clinical literature,
and public web-based databases are searched for studies
that report drug-related genotype–phenotype associa-
tions (see Additional file 1: Table S1 for examples of re-
sources). This initial search is used to identify all genes
in both the pharmacokinetic (PK) and pharmacodynamic
(PD) pathways that have a significant effect on response
to the drug. By definition, such genes have at least one
genetic variant that is significantly and consistently asso-
ciated with a clinically relevant drug response outcome
(altered efficacy or ADR). Literature searches using
PubMed are performed using search terms that include
1) the drug of interest AND ‘genetics OR pharmacogen-
etics OR pharmacogenomics’; 2) the drug and the gene
of interest (for example, key genes in the PK/PD
1. Candidate PGx Drug  
2. Identify Key PGx Gene(s): 
Critical review of published and public data
altered efficacy or adverse reaction); consistently observed in published studies.
For each Gene
3. Identify Drug-Specific Key Genetic Variants:
Review Published/Public data and summarize key gene variant features:
a) Minimum set of DNA variation(s) defining the functional gene variant
b) dbSNP ID,  nucleotide position, mutation effect on protein function and activity, population frequency, key 
publications
4. Drug-Specific Gene Variant Evidence Scoring 5. Partition Variants Based on Evidence
(As described in Table 1) 
For each variant categorization of  Key Publications
Score strength of evidence supporting association 
of each variant with effect on drug response.  
7. Pharmacogenomics Advisory Group (PAG) 
Review of Drug-Gene Summary Data
8. Develop Risk Report
If Approved
Drug-specific Clinically Relevant Variants
Variants Lacking Sufficient Evidence






6. Drug-specific Genotype-Phenotype Interpretation
Inclusion of gene(s) with at least 1 genetic variant associated with clinically relevant drug response (e.g. 
Figure 1 Schematic representation of the Coriell Personalized Medicine Collaborative (CPMC) Pharmacogenomics Appraisal, Evidence-
based Scoring and Interpretation System (PhAESIS) Procedure. Candidate drugs for PGx reporting are identified and prioritized for the CPMC
study based on a number of criteria (as listed in the Methods section). Once a drug is selected for evaluation, the FDA drug label, the peer-
reviewed scientific and clinical literature, and public web-based databases are searched for studies that report drug-related genotype–phenotype
associations (see Additional file 1: Table S1 for examples of resources). This initial search identifies genes with a significant influence on response
to this drug, with at least one genetic variant that is significantly and consistently associated with a clinically relevant drug-response outcome
(altered efficacy or adverse reaction). For each key PGx gene, drug-specific gene variant evidence scoring is carried out (as described in the
Methods section) using the scale depicted in Table 1. Genetic variant evidence scores are used to partition variants based on potential clinical
relevance. Scores of 7 or lower indicate a defined effect on drug response or clinical outcome, whereas those of 8 or higher represent a lack of or
insufficient evidence for an effect. Once all of the genetic variants of potential clinical relevance (those with evidence codes ≤7) have been identi-
fied, the anticipated response of the diploid individual (who possesses two copies of the gene, one inherited from each parent) with each com-
bination of inherited variants is defined, based on published clinical outcomes data. A Punnett square is used to represent distinct diploid
individuals, each assigned a defined drug response phenotype. Curated data from steps 2 to 6 are prepared as PhAESIS summary documents for
review by the CPMC Pharmacogenomics Advisory Group (PAG). If approved by the PAG, drug-specific risk reports are then developed and
released to study participants.
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types of the gene of interest or the commonly used PGx
‘star nomenclature’ [23] for the variations in the gene. In
addition, PGx-specific databases including PharmGKB
[24], the Human Cytochrome P450 (CYP) Allele No-
menclature Committee web site [25], and others are
reviewed for information on genetic variations and their
drug–phenotype association.
Once identified, pharmacogenomic evidence for each
drug-gene pair is summarized in the PhAESIS PAG
submission document, including PK/PD evidence sup-
porting an effect of the gene variant on proteinfunction (for example, enzymatic activity and/or kinet-
ics, plasma drug concentrations, measured difference
in drug target response) and clinical outcome data sup-
porting an association with adverse events or altered
efficacy. This includes information on study design
(such as, observational cohort, randomized controlled
trial, or case–control design; and single study or meta-
analysis), cohort size, and, for prospective studies of
rare clinical outcomes, the numbers of observed
events. In addition, and when available, estimates of
relative effect (hazard ratios, relative risk, odds ratios)
with confidence bounds are noted.
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CPMC scientists review the identified publications and
assess the strength of the evidence they present accord-
ing to the scale depicted in Table 1. The evidence score,
assigned to each variant in a given gene, consists of 14
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onsideration of study design does not resolve the observe inconsistencies, then
nown important substrate-binding or catalytic domain or in a highly evolution-
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(greatest PGx evidence) to D (lowest PGx evidence), as
follows.
A. Clinical outcomes studies. These studies show
measurable difference in clinical endpoints such as
side effects, rate of cure, morbidity, and mortality.
Such studies demonstrate that the genetic variant
significantly changes the medical outcome in
response to the administered drug. Studies in this
category can include clinical trials, cohort studies,
case–control studies, case reports, and case series.
B. PK and PD studies. PK studies are defined as those
that examine the effect of the genetic variant on the
absorption, distribution, metabolism, or elimination
of the drug. In these studies, the genetic variant is
associated with variability in the level or
concentration of the drug and its metabolites at the
site of action. PD studies are defined as those that
examine genetic variants in the drug targets showing
a measureable difference in the biomarker’s response
to the drug. Although the measured variables
(biomarkers) may be considered as surrogates for a
clinical response, they cannot be translated directly
to clinical outcomes as the effect on clinical
outcomes may be insufficiently significant to alter
practice or policy. These studies include in vivo or
ex vivo studies that measure PK or PD responses to
a given drug, and may include clinical trials, cohort
studies, case–control studies, and case reports and
case series.
C. Molecular and cellular functional studies. These
studies use in vitro functional assays to examine how
the genetic variant alters the function of the enzyme
or protein or the whole cell. For example, such
studies might evaluate the effect of the variant on
enzyme kinetics, gene activation, and expression or
alteration of specific cellular properties involved in
the response to a drug.
D. Genetic variation screening studies. These include
studies in which the PGx gene variant was identified
through DNA sequencing analysis or other genetic
analysis, either in control or patient populations,
without any additional functional or clinical studies
to support a functional role for the variant.
Thus, the greatest support comes from clinical out-
comes data (A), followed by PK/PD data (B), followed by
in vitro molecular and/or cellular functional data (C),
with the lowest evidence coming from genetic variation
screening studies (D). Evidence scores (1 to 14) further
differentiate between an effect of the genetic variant dir-
ectly on the drug under review or indirectly on another
drug (such as, another drug or probe substrate; anindustry standard used to evaluate activity of specific
P450 enzymes [26]) (Table 1). If direct evidence is avail-
able for the drug under review, this is considered a sig-
nificant association with the phenotype, regardless of the
level of knowledge about the function of the variant.
However, if only indirect evidence is available for a given
genetic variation, then the evidence is supplemented
based on the variation or mutation type having specific
examples assumed to show a sufficiently broad effect on
the function of the protein to allow extrapolation to an
effect on all drugs (such as, a null mutation that abol-
ishes the protein function; see Table 1 for mutation types
included). For example, evidence codes 1, 5, and 9 are
all based on clinical outcomes data. However, code 1 is
for a direct effect of the variant on the drug under re-
view, whereas codes 5 and 9 are indirect evidence for an
effect on another drug(s). The difference between codes
5 and 9 is that variants with code 5 are expected to have
a universal effect on drug response based on mutation
type, whereas the broader effect of those with code 9 is
either unknown or unsupported based on the type or lo-
cation of the mutation, or based on the observed vari-
able or drug-specific effects. Once all the evidence for a
genetic variant is gathered, a single score is assigned to
each variant based on the greatest strength of evidence
(that is, the lowest evidence code number).
For evidence scores 1 to 7, the drug–phenotype associ-
ation should be consistent across different studies. How-
ever, given the variability in study size and quality in the
published literature, evidence may be weighted in favor
of larger studies and on those that do not raise concerns
about study methods and design (such as use of co-
medications and genotype groupings that might skew
the expected outcomes). If consideration of study quality
resolves apparent inconsistencies, then a score of 1 to 7
is assigned. If the data are inconclusive, the clinical rele-
vance of the variant is unknown, and a score of 9 to 11
is returned, as appropriate.
Identification of drug-specific genetic variants of potential
clinical relevance
Genetic variant evidence scores are used to partition
variants based on potential clinical relevance. Gene vari-
ant evidence scores of less than 7 indicate a defined ef-
fect on drug response or clinical outcome, whereas
those greater than 8 represent a lack of or insufficient
evidence for an effect (Table 1). Within the former
group of variants with defined effect on drug response,
those with evidence code 1 include variants that have
validated clinical evidence to support their effect (that is,
they are considered clinically relevant); those with evi-
dence codes 2 to 7 lack clinical outcomes data but have
been found to have a measurable difference in drug re-
sponse (they are potentially clinically relevant). Variants
Gharani et al. Genome Medicine 2013, 5:93 Page 6 of 19
http://genomemedicine.com/content/5/10/93with evidence codes 8 to 14 are those that either have
limited or inconsistent data for response to other drug(s)
(clinical relevance unknown), or lack supportive data for
response to the drug under review (clinical relevance
unsupported). An evidence score of 8 or higher also
highlights possible gaps in scientific or clinical data. This
group is typically enriched for variants rare in Caucasian
populations or those with undefined effect on the pro-
tein function.
For each gene, drug-specific gene variant summary
tables are prepared, and included in the PAG submission
document. These include information on the minimum
set of DNA variations (such as single nucleotide
polymorphisms (SNPs), insertion/deletions, or copy
number variations) defining the functional gene variant
(such as, haplotype or star allele). For each variation, the
reference SNP ID number (rs#), the nucleotide change,
mutation effect, and variant frequency in populations of
Caucasian, East Asian, and African descent are recorded.
In addition, for each gene variant, the effect on protein
function and activity, the associated metabolic or PK/PD
phenotype, and the strength of evidence score of the
variant-response association, is provided. See Additional
file 1: Tables S3, S6, S9, S11, S13, S15, S20, S23, and S27
for examples of the gene variant summaries in the con-
text of different drugs.
Drug-specific genotype-phenotype interpretation
Once all of the genetic variants of potential clinical rele-
vance (those with evidence codes of 7 or higher) have
been identified, the anticipated response of the diploid
individual (who possesses two copies of the gene, one
inherited from each parent) with each combination of
inherited variants, is defined. If published guidelines
based on empirical data are available, these will be used
to classify diplotypes to specific drug response groups.
For example, the CYP2D6 metabolizer type or activity
level for an individual is predicted based either on their
highest functioning CYP2D6 allele [27,28] or on an al-
lele/genotype scoring approach [29-32]. If specific guide-
lines are not available, assignment of drug response
phenotype is based on observations from published clin-
ical outcomes data for the specific drug-gene pair. In
some cases where there is a lack of published data for a
specific diplotype, the predicted phenotype will be un-
known. Likewise, if there are ambiguities in the pub-
lished data, either due to inconsistent observations or
due to consistent data with an effect in the opposite dir-
ection to that expected, an unknown clinical phenotype
is assigned to the diplotype. All of these examples of
data ambiguity (discordant or insufficient published
data) highlight gaps in knowledge for further study.
In cases of rare observations where data exists for other
alleles of similar effect, the phenotype for a given diplotypeis extrapolated based on the general rules for other similar
variants/genotypes. For example, CYP2C19*6 is a rare vari-
ant that results in negligible catalytic activity towards the
universal CYP2C substrate tolbutamide, and is classified as
a reduced activity variant similar to CYP2C19*2 and
CYP2C19*3. Diplotypes carrying CYP2C19*6 are therefore
assumed to have a similar response to clopidogrel as those
with the CYP2C19*2 variant.
As part of the data curation process, a Punnett square
is used to represent distinct diploid individuals, each
assigned with a defined drug response phenotype. A
‘simple’ Punnett square is first constructed to provide
the general rules used for interpretation of genotype-
drug response phenotype (Figure 2). These rules are
then extended to a ‘full’ Punnett square that includes all
the potential diplotypes for the drug-gene pair under re-
view. Drug response phenotypes represented in the Pun-
nett square tables include both PK/PD and clinical
response data. In cases where the data for specific diplo-
types are ambiguous (discordant or insufficient pub-
lished data) the phenotype assignment will be ‘unknown’
(Figure 2). In cases of genetic variation in genes that en-
code drug-metabolizing enzymes, the phenotype is based
both on a ‘metabolizer’ type and on the drug-specific
clinical outcome (as it relates to efficacy or ADR) that is
associated with the particular genotype. Similarly, for a
drug transporter gene, the genotype associated pheno-
type may be decreased, normal, or increased transport,
which may be associated with reduced efficacy and/or
risk of an ADR. It is also important to note that the pre-
dicted PK/PD phenotype for a specific diplotype may
vary by drug. For example, for the drug-metabolizing en-
zyme CYP2C19, the CYP2C19*1/*17 diplotype is associ-
ated with an unknown metabolizer status (unk) with
respect to proton pump inhibitors (PPIs), but an ultra-
rapid metabolizer (UM) phenotype with respect to clopi-
dogrel (see Additional file 1: Tables S4 and S7).
The CPMC PAG
The CPMC PAG, founded in 2010, is an expert advisory
panel of pharmacists, geneticists, a bioethicist, pharma-
cologists, and clinicians with experience in PGx (see the
CPMC advisory board web site [33] for PAG member-
ship). The group, made up of a chair and associate
members, meets at least once per year to review PhA-
ESIS documents, and advise the CPMC scientific study
team on whether and how to incorporate each drug-
gene pair under consideration into the CPMC study.
PhAESIS documents, submitted to the PAG for review,
comprise a detailed appraisal of the drug and drug-
specific PGx, and provide a summary of curated data
from steps 2 to 6 (above and in Figure 1). Each drug-
specific document includes a description and mechanism
of action of the drug, summary of the key publications
Gharani et al. Genome Medicine 2013, 5:93 Page 7 of 19
http://genomemedicine.com/content/5/10/93supporting the PGx evidence, and the PhAESIS evidence
scoring of key genetic variants, drug-specific genotype-
phenotype correlations and predicted drug response
interpretations. If for a given drug-gene pair, there are in-
consistencies in the published data (for the gene or specific
variants) that render the data inconclusive, the CPMC may
still choose to include these in the PhAESIS report, and to
seek guidance from the PAG on the validity of the data.
Functioning in a similar way to a standard study sec-
tion, the PAG discusses the content of the PhAESIS
document, with commentary by primary and secondary
reviewers. The members discuss the material in a group
setting, with the opportunity to question the CPMC sci-
entific team. After discussion, the PAG votes on whether
and how to include the drug-gene pair in the CPMC.
The PAG advises the CPMC study on: 1) what PGx rele-
vant drug-gene information is sufficiently valid and has
potential clinical utility (is at a minimum potentially
clinically relevant), and is therefore worthy of release to
study participants as personalized PGx results; and 2)
defining whether and what genetic results for a particu-
lar drug-gene pair constitute a level of drug response
‘actionability’ that may obligate a different (more urgent)
communication path to participants. For example, study
participants who are predicted to have diminished effect-
iveness of clopidogrel due to CYP2C19 poor metabolizer
status would warrant a higher level of messaging via the
web portal than would extensive metabolizers. This
phenotype-specific messaging ensures that such partic-
ipants have made an informed decision regarding
whether or not to view their results. This approach is
faithful to the study premise and original consent,
which leaves to each study participant the decision to










Figure 2 Example of a simple Punnett square providing general rules
for a particular drug-metabolizing pharmacogenomics (PGx) gene. An
EM, extensive metabolizers; IM, intermediate metabolizers; PM, poor metab
phenotype currently unknown. Note that for other types of PGx genes such
in the Punnett square table, for example as ‘normal’ for normal transport; ‘d
Annotation of the associated clinical outcome: shades of blue indicate ‘nor
(ADR) or altered efficacy resulting from deficiency or reduced function/acti
verse drug reaction/altered efficacy resulting from protein deficiency or red
excess or increased function of the protein product; pink, unknown pheno
phenotype represent a gap in knowledge where further research is warranCPMC study PGx risk reporting
Once approved by the PAG, the drug-gene specific
genotype-phenotype assignments summarized in the ex-
tended Punnett square table (see Additional file 1: Tables
S4 and S7) are used to develop personalized PGx risk re-
ports for release to CPMC participants. The process for
developing PGx reports falls outside the scope of the
PhAESIS system described here, and will not be detailed
in this paper. Briefly, the CPMC develops drug-specific
genotype translation tables and information technology
infrastructure for dynamically extracting personal data
(genetic results for multiple variants, and relevant demo-
graphics) from the project database in order to generate
personalized risk reports. PGx risk reports are delivered
through the secure CPMC web portal (example reports
can be viewed at the CPMC web site [34]) Risk reports
provided to CPMC participants contain PGx genetic
results, result interpretation, educational summaries,
detailed information on genetic and non-genetic risk fac-
tors affecting drug response, and the range and fre-
quency of drug response phenotypes in the population
most relevant to the participant (Caucasian, African, or
East Asian ancestry). Limitations, methods, and links to
external resources are also provided through the web-
based report. To aid participants’ understanding, the
CPMC provides them with access to free counseling by
board-certified genetic counselors and pharmacists.
Results
To date the PAG has reviewed PhAESIS reports on
more than 11 drugs and 18 associated PGx genes. Seven
drugs/drug class and nine associated genes have been
approved for PGx reporting to CPMC participants (clo-







for assignment of predicted drug-specific response phenotypes
notation of pharmacokinetics/pharmacodynamics (PK/PD) outcome:
olizers; UM, ultra-rapid metabolizers; unknown, drug metabolizing
as drug transporters, the PK/PD phenotype can be similarly annotated
ecreased’ for reduced transport; and ‘increased’ for increased transport.
mal’ response to the drug; yellow, most extreme adverse drug reaction
vity of the PGx protein product; orange, clinically distinct or milder ad-
uced function; purple, distinct ADR or altered efficacy resulting from
type for the defined diplotype. The group of diplotypes with unknown
ted.
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thiopurines and TPMT; simvastatin and SLCO1B1; cele-
coxib and CYP2C9). One drug-gene pair (tamoxifen and
CYP2D6) has been deferred pending more data, and
three have been rejected for various reasons, including
insufficient clinical data or lack of evidence for clinical
utility. A summary of the PAG review outcomes is pro-
vided in Table 2. The deferral of a decision on tamoxifen
and CYP2D6 is an example of how the PAG can provide
expert guidance in situations where the published data
are ambiguous. The large body of data evaluating the
prognostic and predictive relevance of CYP2D6 gene
testing to guide tamoxifen therapy for breast cancer was
inconsistent, and the CPMC chose to present these to
the PAG for specific guidance. After deliberation, the
PAG deemed the data inconclusive, and given that data
from a large clinical study was anticipated (the Inter-
national Tamoxifen Pharmacogenomics Consortium
(ITPC) [35]), the vote on this drug-gene pair was de-
ferred pending that publication.Table 2 Summary of the Coriell Personalized Medicine Collab
by the Pharmacogenomics Advisory Group
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aGenetic results that warrant additional communication to participants who are at i
b‘Low dose’ is defined as a daily therapeutic dose of 0.5 to 2 mg based on the FDADrug response interpretations for the PAG-approved
drug-gene pairs are summarized (Tables 3, 4, 5, 6, 7, 8, and
9). These tables include gene variants with evidence scores
of 7 or higher defined during the PhAESIS evaluation of
each drug-gene pair (see Additional file 1: Sections 1 to 7
for abbreviated curated data from PAG submissions, in-
cluding variant summary tables, genotype-phenotype inter-
pretation Punnett squares, and PGx evidence for each of
the approved drug-gene pairs). The tables include genetic
results with validated clinical evidence (Tables 3, 4, 5, 6, 7,
8, and 9), considered to be clinically relevant (those that in-
clude variants with evidence code 1) (see Additional file 1:
Tables S3, S6, S9, S11, S13, S15, S20, S23, and S27). Genetic
results that include variants with evidence codes 2 to 7 (po-
tentially clinically relevant) are also included (Tables 3, 4, 5,
6, 7, 8, and 9); however, these require further validation to
support their inclusion for clinical reporting. For each of
the drug-specific genotype categories, both the PK/PD
phenotype and the associated clinical phenotype (drug re-
sponse outcome and interpretation) are provided. If specificorative drug-gene pharmacogenomics reports evaluated
on for rejection/deferral Highly actionable genetic
resultsa
l support for GGCX at time of
tion
Low warfarin dose requirementb
Poor metabolizers
rognostic and predictive relevance of
o guide tamoxifen therapy for breast
clusive. Vote has been deferred
ion of anticipated clinical trials data
Vote deferred
Ultra-rapid metabolizers
idence, and given prescribing






al consequences is weak NA
: evidence for clinical utility is lacking Simvastatin and SLCO1B1:
genetic results associated with
decreased hepatic drug uptake
*3/*3
ecent evidence for lower penetrance
y variants, and a lack of good
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Table 3 Genotype-phenotype drug response interpretations of the Pharmacogenomics Advisory Group-approved drug-gene pair clopidogrel and CYP2C19a







CYP2C19*1/*1 38 36 35.5 EM: normal enzymatic function and
normal drug activation; normal platelet
inhibition
Likely to have a normal response





Additional file 1: Table
S4)
19 22 46 IM: reduced enzymatic function resulting
in reduced drug activation; decreased
platelet inhibition
Increased risk of ischemic event






Additional file 1: Table
S4)
2 3 15 PM: greatly reduced or abolished
enzymatic function, leading to little or
no drug activation; greatly diminished
platelet inhibition
Increased risk of ischemic event
while on clopidogrel.d Should use
alternative anti-platelet
medication
CYP2C19 PMs with ACS or undergoing PCI treated with
Plavix at recommended doses exhibit higher
cardiovascular event rates than do patients with normal
CYP2C19 function. Consider alternative treatment or




34 31 2 UM: enhanced enzymatic function
leading to greater drug activation
Possible increased risk of bleeding;
but also likely to derive greater





(see Additional file 1:
Table S4)
7 8 1.5 Unk: metabolizer status undetermined
and therefore unknown. PD data
indicates platelet response is
intermediate between likely IMs and EMs
Unknown effect on drug response –
Abbreviations: ACS acute coronary syndromes, EM Extensive metabolizer, FDA Food and Drugs Administration, IM intermediate metabolizer, PCI percutaneous coronary intervention, PD pharmacodynamic, PK
pharmacokinetic, PM poor metabolizer, UM Ultra-rapid metabolizer, Unk metabolizer status unknown.
aSupporting evidence may be found in Additional file 2: Section S1.0-1.7, and Additional file 1:Tables S2-S4. These include summaries of the PhAESIS evaluation and referenced publications supporting the drug-gene
clinical phenotypes.
bDiplotypes with frequencies of less than 0.4% in Caucasians are included above. Other rare diplotypes that fall under the same phenotype category can be found in the genotype-phenotype Punnett table (see
Additional file 1: Table S4). Diplotypes above and in the genotype-phenotype Punnett table include both clinically validated genetic results (those that include variants with evidence code 1) and results that include
variants with evidence scores 2 to 7 (potentially clinically relevant). The latter require further validation to support their inclusion for clinical reporting.
cPopulation frequencies are estimated based on reported gene variant allele frequencies (see Additional file 1: Table S3) and Hardy-Weinberg principles.

















Table 4 Genotype-phenotype drug response interpretations of the Pharmacogenomics Advisory Group-approved drug-gene pairs proton pump inhibitors and
CYP2C19a







CYP2C19*1/*1 38 35 35 EM: normal enzymatic function and normal
drug elimination
Likely to have normal response to standard dose of PPIs –
CYP2C19*1/*2, CYP2C19*1/*8,
CYP2C19*2/*17, and other rare
diplotypes (see Additional file 1:
Table S7)
26 31 48 IM: reduced enzymatic function leading to
reduced drug elimination and greater drug
exposure
Both IM and PM likely to have improved PPI efficacy at
standard dose of PPI as measured by intragastric pH, duration
of inhibition, and cure rates for GERD and Helicobacter pylori
–
CYP2C19*2/*2 and other rare
diplotypes (see Additional file 1:
Table S7)
2 3.5 15 PM: greatly reduced or abolished enzymatic
function, leading to reduced drug elimination
and greater drug exposure
–
CYP2C19*17/*17 5 4.5 0.04 UM: enhanced enzymatic function leading to
greater drug elimination and reduced drug
exposure
Decreased PPI efficacy at standard doses –
CYP2C19*1/*17 29 26 2 Unk: metabolizer status undetermined and
therefore unknown; PD data shows platelet
response is intermediate between IMs and EMs
Unknown effect on drug response
Abbreviations: EM Extensive metabolizer, FDA Food and Drugs Administration, GERD gastroesophageal reflux disease, IM intermediate metabolizer, PD pharmacodynamic, PK pharmacokinetic, PM poor metabolizer, PPI
proton pump inhibitors, UM Ultra-rapid metabolizer, Unk metabolizer status unknown.
aSupporting evidence may be found in Additional file 2: Section S2.0-2.7, and Additional file 1: Tables S5 and S7. These include summaries of the PhAESIS evaluation and referenced publications supporting the drug-
gene clinical phenotypes.
bDiplotypes with frequencies of less than 0.4% in Caucasians are included above. Other rare diplotypes that fall under the same phenotype category can be found in the genotype-phenotype Punnett table (see
Additional file 1: Table S7). Diplotypes above and in the genotype-phenotype Punnett table include both clinically validated genetic results (those that include variants with evidence code 1) and results that include
variants with evidence scores 2 to 7 (potentially clinically relevant). The latter require further validation to support their inclusion for clinical reporting.

















Table 5 Genotype-phenotype drug response interpretations of the Pharmacogenomics Advisory Group-approved drug-gene pair celecoxib and CYP2C9







CYP2C9*1/*1 67 84.5 92 EM: normal enzymatic
function and drug
elimination
Expected to have a normal analgesic response at standard
dose of celecoxib. Colorectal adenoma treatment: no
additional efficacy with 400 mg celecoxib twice daily
compared with 200 mg twice daily
–
CY2C9*1/*2, CYP2C1/*3, and
other rare diplotypes (see
Additional file 1: Table S10)




Insufficient data; predicted risk of side effects is unknown –
CYP2C9*3/*3, CYP2C*2/*3,
CYP2C*2/*2, and other rare
diplotypes (see Additional
file 1: Table S10)
3 0.6 0.2 PM: greatly reduced
enzymatic function and drug
elimination, leading to
greater drug exposure
Greater risk of adverse cardiovascular events with 400 mg
celecoxib twice daily. Colorectal adenoma treatment:
decreased recurrence with 400 mg celecoxib twice daily
Consider 50% of the standard
starting dose in PMs; consider
alternative treatment in PMs with
juvenile rheumatoid arthritis
Abbreviations: EM Extensive metabolizer, FDA Food and Drugs Administration, IM intermediate metabolizer, PD pharmacodynamic, PK pharmacokinetic, PM poor metabolizer.
aSupporting evidence may be found in Additional file 2: Section S3.0 to 3.7 and Additional file 1: Tables S8 to S10. These include summaries of the PhAESIS evaluation and referenced publications supporting the drug-
gene clinical phenotypes.
bDiplotypes with frequencies of less than 0.4% in Caucasians are included above. Other rare diplotypes that fall under the same phenotype category can be found in the genotype-phenotype Punnett table (see
Additional file 1: Table S10). Diplotypes above and in the genotype-phenotype Punnett table include both clinically validated genetic results (those that include variants with evidence code 1) and results that include
variants with evidence scores 2 to 7 (potentially clinically relevant). The latter require further validation to support their inclusion for clinical reporting.

















Table 6 Genotype-phenotype drug response interpretations of the Pharmacogenomics Advisory Group-approved drug-gene pairs: warfarin and CYP2C9/VKORC1/CYP4F2a








CYP2C9*1/*1 67 76 88 EM: normal enzymatic function
and normal drug elimination
Expected to have a normal response
at standard dose of warfarin
The warfarin drug label includes a table of CYP2C19 and
VKORC1 genotype-based therapeutic dosing guidelines,
which provides the range of expected therapeutic doses
based on genotype combinations (based on VKORC1
-1639G > A (rs9923231) and CYP2C9*2 and CYP2C9*3 var-
iants) (see Additional file 1: Table S17)
CYP2C9*1/*2, CYP2C9*1/*14
and other rare diplotypes (see
Additional file 1: Table S12)
20 17 4 IM: reduced enzymatic function,
leading to reduced drug
elimination and greater drug
exposure
At increased risk of bleeding at
standard dose of warfarin.d. Takes
longer to reach therapeutic INR;
requires lower dose of warfarin
CYP2C9*1/*3, CYP2C*2/*2,
CYP2C*2/*3, CYP2C*3/*3, and
other rare diplotypes (see
Additional file 1: Table S12)
13 7 8 PM: greatly reduced enzymatic
function, leading to reduced
drug elimination and greatly
increased drug exposure
At increased risk of bleeding at
standard dose of warfarin.d Takes
longer to reach therapeutic INR;
requires lower dose of warfarin
Warfarin and VKORC1
−1639G > A (rs9923231): GG 40 74 1 Normal mRNA expression;
normal enzyme activity and
efficient vitamin K cycling
Associated with a requirement for
higher therapeutic warfarin dose.d
Potentially at increased risk of
thrombosis at standard dose
−1639G > A (rs9923231): GA 47 24 20 Reduced mRNA expression;
reduced enzyme activity and
vitamin K cycling
Associated with a requirement for
intermediate therapeutic warfarin
dosed
−1639G > A (rs9923231): AA 13 2 79 Greatly reduced mRNA
expression level; significant
reduction in enzyme activity
and vitamin K cycling
Associated with a requirement for
lower therapeutic warfarin dose.d
Potentially at increased risk of
bleeding events
Warfarin and CYP4F2
1297G > A, CYP4F2 V433M: GG 53 83 63 Higher CYP4F2 activity results in
reduced hepatic vitamin K levels
Associated with a requirement for
lower therapeutic warfarin dose.d
Potentially at increased risk of
bleeding events
–
1297G > A, CYP4F2 V433M: GA 40 16 33 Intermediate CYP4F2 activity
results in intermediate hepatic
vitamin K levels




1297G > A, CYP4F2 V433M: AA 7 1 4 Reduced CYP4F2 activity results
in increased hepatic vitamin K
levels
Associated with a requirement for
higher therapeutic warfarin dose.d
Potentially at increased risk of
thrombosis at standard dose
–
Abbreviations: EM Extensive metabolizer, FDA Food and Drugs Administration, IM intermediate metabolizer, INR international normalized ratio, PD pharmacodynamic, PK pharmacokinetic, PM poor metabolizer.
aSupporting evidence may be found in Additional file 2: Section S4.0 to 4.7 and Additional file 1: Tables S11 to S17. These include summaries of the PhAESIS evaluation and referenced publications supporting the
drug-gene clinical phenotypes.
bDiplotypes with frequencies of less than0.4% in Caucasians are included above. Other rare diplotypes that fall under the same phenotype category can be found in the genotype-phenotype Punnett tables (see
Additional file 1: Tables S12, S14 and S16). Diplotypes above and in the genotype-phenotype Punnett tables include clinically validated genetic results (those that include variants with evidence code 1).
cPopulation frequencies are estimated based on reported gene variant allele frequencies (see Additional file 1: Table S11, S13 and S15) and Hardy-Weinberg principles.
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http://genomemedicine.com/content/5/10/93FDA PGx guidelines are available for the drug-gene cat-
egory, these are indicated along with the expected
population frequencies for Caucasian, African, and East
Asian ancestries.
During the PhAESIS evaluation process, gaps in scien-
tific and clinical evidence for specific gene variants and
variant combinations are highlighted for further study.
Gaps in knowledge for each of the drug-gene pairs pre-
sented in this report are summarized in the respective
‘Gaps in PGx knowledge’ subsection of Additional file 2:
Sections S1 to S7. Broadly, these include the following:
1) Limited published PGx data for many of the drug-
gene pairs evaluated. Although all show clinical val-
idity for at least one genetic result (association with
an altered clinical outcome) most lack sufficient
data, having only a limited number of studies dem-
onstrating a clear association with drug response or
tolerance (for example only evidence linking
CYP2C9*3/*3 genotype and celecoxib-CYP2C9 toler-
ance; mostly case report-based evidence linking co-
deine ADRs and CYP2D6 UM metabolizer status;
and limited data on CYP2C19*17 genotypes and PPI
efficacy).
2) In particular, there are limited data on rare or
ancestry-specific variants with respect to effects on
protein function or drug-specific clinical response
(typically variants with evidence codes ≥8).
3) A general need to expand basic and clinical research,
given that the greatest body of published data comes
from Caucasian populations, and therefore has
limited application to the general world population
(typically for variants with evidence code ≥2).
4) Missing genotype data on other known functional
variants in the gene(s) under evaluation,
confounding the interpretation of published drug
response results (for example, the lack of genotype
data on other loss of function variants and
CYP2C19*17 in many of the earlier PGx studies of
this gene; similarly, lack of qualitative and
quantitative data on CYP2D6 copy number variants).
5) Lack of data on haplotype structure/phase with
possible subsequent confounding of drug response
interpretation (for example, the effect of SLCO1B1
variant N130D on simvastatin response (see
Additional file 2: Section S7)); another example
includes the presence of rare alleles such as the
CYP2C19*17 variant in cis with either a CYP2C19*2
or CYP2C19*4 allele as observed in the CPMC
cohort (data not shown) and reported by others
[38]. Given that most studies are population-based
rather than family-based, and therefore lack
phasing information, the presence of double het-
erozygotes for these variants may lead tomisinterpretation of the true metabolizer type (for
exam ple, a
CYP2C19*2/CYP2C19*17 intermediate metabolizer
for PPI response vs. CYP2C19*1/CYP2C19*2
+CYP2C19*17, for which metabolizer type is
unknown).
Discussion
In order to implement PGx reporting in the CPMC, and
to facilitate interpretation and dissemination of personal-
ized PGx data to the study participants, the CPMC set
out to gather, systematically review, and critically ap-
praise published and public PGx data from a variety of
sources. An evidence-based scoring system was devel-
oped to parse the clinical relevance of gene variants in
the context of specific drugs.
The CPMC PhAESIS method has several key
strengths: 1) By taking a drug-centered approach, the
full extent of current PGx knowledge is summarized,
allowing simultaneous identification of genetic results
with sufficient data to support clinical diagnostic appli-
cations, and highlighting the questions that remain to be
answered. 2) The multi-tier evidence scoring system al-
lows all published and supported key functional variants
to be identified, including those in minority ethnic and
racial populations. 3) The scoring system provides an in-
valuable overview of what genetic data are clinically sup-
ported and where gaps in knowledge exist. Filling these
gaps is crucial to the successful development of diagnos-
tic tools that are able to identify all patients likely to
benefit from the targeted personalized drug therapies. 4)
Another key feature of the CPMC PhAESIS system is
the use of an external expert advisory panel to vet the
results of the systematic review. This approach adds fur-
ther weight to the conclusions and interpretations of the
data to be reported. The PAG also provides guidance on
which subset of genetic results for a particular drug are
of sufficient clinical significance (highly actionable) and
therefore warrant a higher level of communication with
CPMC study participants (Table 2).
The CPMC is not alone in recognizing the need to de-
velop a system that distills the published research data
into clear and evidence-based therapeutic guidelines to
ease the implementation of PGx in clinical practice.
There are several other groups and organizations work-
ing to collate the research literature using a gene specific
approach. These include, among others, the PharmGKB,
a web-based database of curated and annotated data on
PGx gene variants and gene-drug-disease relationships
[24]; the Human Cytochrome P450 (CYP) Allele No-
menclature Committee website, which provides updated
information on PGx relevant genetic variations of
human CYP enzymes [25]; and the Cytochrome P450
Drug Interaction Table at Indiana University School of
Table 7 Genotype-phenotype drug response interpretations of Pharmacogenomics Advisory Group-approved drug-gene pair: Codeine and CYP2D6a







CYP2D6*1/*9, CYP2D6*1/*10, and other
rare diplotypes (see Additional file 1:
Table S21)d
80 69 45 EM: normal enzymatic
function and normal
conversion of codeine to
morphine
Normal analgesic response to




CYP2D6*9/*41, CYP2D6*10/*41, and other
rare diplotypes (see Additional file 1:
Table S21)




Reduced analgesic response (pain
relief). May require an increased
dose to obtain an analgesic effect




CYP2D6*4/*7 and other rare diplotypes
(see Additional file 1: Table S21)
8 3 14 PM: greatly reduced or
abolished enzymatic
function, leading to greatly
reduced conversion of
codeine to morphine
Little or no analgesic response
(pain relief). Should consider
alternative pain medication
–
Rare in Caucasians. The following are
common in East Asians: CYP2D6*1/*1 × N,
CYP2D6*1 × N/*1 × N, CYP2D6*1 × N/*4,
CYP2D6*1 × N/*5, CYP2D6*1 × N/*10,
CYP2D6*1 × N/*10C(*36)
<0.1 2 15 UM: enhanced enzymatic
function, leading to
greater conversion of
codeine to morphine and
higher drug exposure
Increased risk of drug toxicity and
ADRs. Should consider alternative
pain medication
CYP2D6 PMs and UMs may experience
different efficacy. Even at labeled dosage
regimens, UMs may experience overdose
symptoms. Use of codeine by UM mothers
can potentially lead to serious ADRs,
including death, in nursing infants
Abbreviations: ADR adverse drug reaction, EM Extensive metabolizer, FDA Food and Drugs Administration, IM intermediate metabolizer, PD pharmacodynamic, PK pharmacokinetic, PM poor metabolizer, UM
Ultra-rapid metabolizer.
aSupporting evidence may be found in Additional file 2: Section S5.0 to 5.7 and Additional file 1: Tables S19 to S21. These include summaries of the PhAESIS evaluation and referenced publications supporting the
drug-gene clinical phenotypes.
bDiplotypes with frequencies of less than 0.4% in Caucasians are included above. Other rare diplotypes that fall under the same phenotype category can be found in the genotype-phenotype Punnett table (see
Additional file 1: Table S21). Diplotypes above and in the genotype-phenotype Punnett table include both clinically validated genetic results (those that include variants with evidence code 1) and results that include
variants with evidence scores 2 to 7 (potentially clinically relevant). The latter require further validation to support their inclusion for clinical reporting.
cPopulation frequencies are estimated based on reported gene variant allele frequencies (see Additional file 1: Table S20) and Hardy-Weinberg principles.

















Table 8 Genotype-phenotype drug response interpretations of the Pharmacogenomics Advisory Group-approved drug-gene pairs: thiopurines and TPMTa







TPMT*1/*1 94 81 97 EM: normal enzymatic function
and normal drug elimination
Expected to respond to a standard dose of thiopurine
drugs. Not at increased risk of drug toxicity
–
TPMT*1/*2, TPMT*1/3A, and
other rare diplotypes (see
Additional file 1: Table S24)
6 18 3 IM: reduced enzymatic function,
leading to reduced drug
elimination and greater drug
exposure
At increased risk of drug toxicity such as
myelosuppression when taking standard dose of
thiopurine drugs. Risk of side effects can be reduced
by reducing standard dose by 50 to 70%
Heterozygous patients with low or
intermediate TPMT activity are more
likely to experience toxicity
Rare in Caucasians, The
following are more common
in African ancestry: TPMT*3A/
*3A, TPMT*3B/*3B
0.1 1 0 PM: very low or absent enzymatic
function, leading to greatly
reduced drug elimination and
increased drug exposure
At increased risk of drug toxicity such as
myelosuppression when taking thiopurine drugs.
Should consider alternative medication
Homozygous-deficient patients (two
non-functional TPMT alleles) given
usual dose of thiopurines are at in-
creased risk of toxicity
Abbreviations: EM Extensive metabolizer, FDA Food and Drugs Administration, IM intermediate metabolizer, PD pharmacodynamic, PK pharmacokinetic, PM poor metabolizer.
aSupporting evidence may be found in Additional file 2: Section S6.0 to 6.7 and Additional file 1: Tables S22 to S24. These include summaries of the PhAESIS evaluation and referenced publications supporting the
drug-gene clinical phenotypes.
bDiplotypes with frequencies of less than 0.4% in Caucasians are included above. Other rare diplotypes that fall under the same phenotype category can be found in the genotype-phenotype Punnett table (see
Additional file 1: Table S24). Diplotypes above and in the genotype-phenotype Punnett table include both clinically validated genetic results (those that include variants with evidence code 1) and results that include
variants with evidence scores 2 to 7 (potentially clinically relevant). The latter require further validation to support their inclusion for clinical reporting.

















Table 9 Genotype-phenotype drug response interpretations of the Pharmacogenomics Advisory Group-approved drug-gene pairs simvastatin and SLCO1B1a





SLCO1B1*1/*1 64 92 79 Normal drug transport Normal response and risk of adverse
drug reactions to simvastatin
80 mg simvastatin
maximum dose
SLCO1B1*1/V174A, SLCO1B1*1/*6, and another rare diplotype,
SLCO1B1*1/*3
32 8 20 Intermediate decreased
drug transport




SLCO1B1 V174A/V174A, SLCO1B1*6/V174A, and other rare
diplotypes (see Additional file 1: Table S28)
4 <1 1 Decreased drug
transport




Abbreviations: FDA Food and Drugs Administration, PD pharmacodynamic, PK pharmacokinetic.
aSupporting evidence may be found in Additional file 2: Section S7.0 to 7.7 and Additional file 1: Tables S26 to S28. These include summaries of the PhAESIS evaluation and referenced publications supporting the
drug-gene clinical phenotypes.
bDiplotypes with frequencies of less than 0.4% in Caucasians are included above. Other rare diplotypes that fall under the same phenotype category can be found in the genotype-phenotype Punnett table (see
Additional file 1: Table S28). Diplotypes above and in the genotype-phenotype Punnett table include both clinically validated genetic results (those that include variants with evidence code 1) and results that include
variants with evidence scores 2 to 7 (potentially clinically relevant). The latter require further validation to support their inclusion for clinical reporting.

















Gharani et al. Genome Medicine 2013, 5:93 Page 17 of 19
http://genomemedicine.com/content/5/10/93Medicine [20], which provides lists and publication ref-
erences for drug-gene interactions. These are invaluable
tools for researchers, including the CPMC. In the case of
the drug interaction website, whose primary goal has
been to provide information that can mitigate ADRs in
polypharmacy settings, this resource is utilized by clini-
cians and researchers alike.
Other, more targeted efforts aimed at providing clin-
ical pharmacogenomics guidelines that can be utilized
by diagnostics developers and healthcare providers in-
clude those of the Clinical Pharmacogenetics Implemen-
tation Consortium (CPIC), established by the National
Institutes of Health Pharmacogenomics Research Net-
work and PharmGKB [39], and the Pharmacogenetics
Working Group (PWG), established by the Royal Dutch
Association for the Advancement of Pharmacy [40,41].
Another initiative, aimed at establishing a systematic,
evidence-based process for assessing genetic tests and
other applications of genomic technology in transition
from research to clinical and public health practice, is
the CDC-sponsored Evaluation of Genomic Applications
in Practice and Prevention (EGAPP) [42]. The EGAPP
initiative evaluates tests such as those for predictive
testing for inherited risk of common diseases and
pharmacogenetic testing for variation in drug response.
All three of these groups aim to provide peer-reviewed
guidelines for pharmacogenetics-based therapeutic (dose)
recommendations. All have developed a process that in-
volves systematic review of published literature, scoring of
evidence for drug phenotype or genotype categories, and
interpretation of this evidence to guide therapeutic recom-
mendations. Like the CPMC, CPIC, PWG, and EGAPP also
employ expert panels of researchers and clinicians working
in the field of study to guide the evaluation process and
resulting recommendations. However, the CPMC is unique
in that the expert advisory panel is independent of the
CPMC study and includes a broader representation of
stakeholders including practicing physicians and an ethicist.
In addition, CPMC PAG evaluation and approval occurs in
the context of a research study, and the threshold for
reporting may be lower, compared with the goals of CPIC
and PWG, in order to include genetic variants that are po-
tentially clinically relevant. For example, Swen et al. (PWG)
[40] included CYP2C19*2, CYP2C19*3 and CYP2C19*17
only in their metabolizer type classifications, and the CPIC
publications placed a greater emphasis on variants common
in Caucasian populations for which there is a greater body
of data (such as the *2 and *3 alleles of both CYP2C19 and
CYP2C9), although reference to other variants of potential
effect are made in the supplementary materials sections of
the publications [36,43]. Such variants (typically those with
an evidence score of 2 to 7) are highlighted by the PhAESIS
evaluation as needing further clinical validation by the
CPMC or other researchers to support their clinical utility.Like the CPMC approach, evidence scoring by CPIC,
PWG, and EGAPP is based on level or strength of
evidence and clinical relevance [39-41]. However, the
CPMC tiered evidence scoring method allows clearer
distinction of the clinical relevance of individual PGx
genetic variants, and like the EGAPP effort, highlights
gaps in knowledge for further study. For example, dis-
tinction can be made between a variant with a score of 1
(with published clinical outcomes data for the drug
under review) versus a score of 3 (indicating in vitro
data supporting the effect of the variant on protein func-
tion) versus a score of 5 (clinical outcomes data for an-
other drug) versus a score of 13 (where there are no
functional or clinical data available and the clinical rele-
vance is therefore unknown). The primary goal of CPIC
and PWG is to provide published guidelines for health-
care providers and diagnostics developers for immediate
clinical implementation. PWG has the added advantage
of integrating their recommendations into the Dutch
electronic drug database that is utilized as part of the
clinical automated medication surveillance system [41].
By contrast, the primary goal of the CPMC is to deliver
the PGx genetic interpretations within a research setting
directly to the study participants, to allow both the in-
vestigation of participant understanding and behavior in
response to receiving PGx risk results, and the carrying
out of drug-gene specific discovery and validation re-
search to confirm prior associations and/or address
current gaps in knowledge.
The key limitation of the PhAESIS system is shared by
all of the other described systems for evaluating and
reviewing published and public PGx data, in that all the
systems are limited to the data available at the time of
the initial evaluation. All, including the CPMC, require
efforts to update information on an ongoing basis. In the
context of the CPMC research study, a revision schedule
has not been systematically implemented. However, the
CPMC has brought updates of previously approved
drug-gene pairs to the PAG for re-evaluation in cases
where subsequently published data could potentially re-
verse or modify the original decision of the PAG. This is
the case for CYP2C19 and clopidogrel, which was first
reviewed and approved by the PAG in March 2010 and
re-evaluated in October 2010 following publication of
controversial data in August 2010 [44]. However, these
new data did not affect the approval to release results
for this drug-gene pair, and the results report was subse-
quently implemented and released to study participants.
The CPMC is exploring the use of automation in many
parts of the system to facilitate the PhAESIS process. This
could include automated publication database searches and
prioritization for review and evidence scoring by a scientist
reviewer, and variant data-gathering for many of the tables
included in the reports.
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http://genomemedicine.com/content/5/10/93In addition, like other published approaches, the method
is limited by the available published data both in terms of
the completeness of the genetic data (inclusion of all rele-
vant variants and information on phasing and gene linkage
disequilibrium structure) and the uniformity of study
design and treatment regimen used (including dosing and
duration variability, and disclosure about other concomi-
tant drug therapies).
Another limitation of the PhAESIS approach is that
the evidence scoring was developed specifically for drugs
that are affected by germline or inherited genomic varia-
tions and not those that are affected by somatic muta-
tions, such as in tumor or cancer genomes. Although
specific anticancer drugs (such as thiopurines, tamoxifen,
and 5-fluorouracil) have been evaluated, the published data
for these were based on genomic variants and not on the
analysis of the tumor/cancer genome. In essence, a similar
evidence scoring procedure can be developed that includes
data from either or both inherited and cancer genomic
data. At present, the evidence table is not designed to cap-
ture evidence from the tumor genome, but potentially can
be adapted in the future to include this.
Finally, a limitation not of the PhAESIS method but of
its implementation within the CPMC study is a focus on
genes that are represented on the genotyping platforms
currently used. The CPMC can interrogate 1.8 million
SNPs and insertion/deletions across the genome in the
Affymetrix Genomewide Human 6.0 array, and 1,936 vari-
ants specific to genes for drug absorption, disposition, me-
tabolism, and elimination in the Affymetrix DMET Plus
array. In addition, copy number variation at the CYP2D6
gene can be detected by a recently implemented Luminex®
assay. In the future, adoption of whole genome sequencing
by the project is likely to address this limitation.
Conclusions
In conclusion, the system described here for the evaluation
and translation of PGx data for specific drug-gene interac-
tions has broad application for guiding the develop-
ment of PGx testing for diagnostic use, identifying
gaps in knowledge for further research, and providing
results interpretation guidelines for the education of
stakeholders (healthcare professionals and health con-
sumers). In this way, the CPMC is contributing to ef-
forts facilitating the implementation of PGx into
personalized medical practice.
Additional files
Additional file 1: Contains all the tables (Tables S1 to S28)
referenced in Additional file 2 and in the main manuscript. Note
that, given the research setting, gene variant evaluations were prioritized
to those present on the genotyping platforms used by the Coriell
Personalized Medicine Collaborative (CPMC) study (Affymetrix DMET Plusand Genomewide Human 6.0 arrays). As such the gene variant evidence
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Sections S1 to S7 represent summary annotations of PhAESIS reports
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data are also cited in the text.Abbreviations
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